The purpose of the study is to see whether oral semaglutide can help slow worsening of memory, thinking, and daily function in people with early Alzheimer’s disease, and to check its safety. The study is randomised, which means the treatment is assigned by chance, and double-blind, which means neither the participants nor the study team knows who receives semaglutide or placebo during the study. Treatment is taken by mouth over a long period, and the study follows changes over time.

Participants take the study tablets regularly and are seen at planned visits during the trial. These visits are used to monitor health, review how the person is doing, and record any changes in memory, daily activities, or side effects. The study compares how people do over time in the semaglutide and placebo groups.

The purpose of the study is to evaluate how well AVP-786 works in reducing agitation symptoms in patients with Alzheimer’s-related dementia. Participants in the study will receive either the AVP-786 medication or a placebo. The study is designed to be “double-blind,” meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo, to ensure unbiased results.

Throughout the study, participants will take the medication in capsule form by mouth. The study will last for a set period, during which participants will be monitored for any changes in their symptoms and any side effects they may experience. The goal is to determine if AVP-786 can help manage agitation in patients with Alzheimer’s-related dementia more effectively than a placebo.

The purpose of this study is to determine if remibrutinib is more effective than teriflunomide in reducing the frequency of relapses in people with relapsing forms of MS. Participants in the study will be randomly assigned to receive either remibrutinib, teriflunomide, or a placebo, which is a substance with no active medication. The study will begin with a period where participants receive either remibrutinib or teriflunomide, followed by an extended treatment phase where all participants will receive remibrutinib. This approach helps researchers understand the long-term effects of remibrutinib on MS.

Throughout the study, participants will take the medications orally, and their health will be monitored regularly to assess the impact of the treatments. The study aims to provide valuable information on how well remibrutinib works compared to teriflunomide and to ensure the safety of participants. By participating in this study, researchers hope to find a more effective treatment option for those living with relapsing MS.

The main goal of the study is to see how well CagriSema works at lowering blood sugar levels compared to semaglutide alone, as measured by a blood test called HbA1c that shows average blood sugar over several months. The study will also look at how these medications affect body weight, blood pressure, cholesterol levels, and other health measurements. Researchers want to understand if the combination medication works better than the individual medications at helping people reach target blood sugar levels and lose weight. The study will also measure how much time blood sugar levels stay within a healthy range using a continuous glucose monitor, which is a small device that tracks sugar levels throughout the day.

Participants will receive their assigned treatment for 68 weeks, with the entire study lasting about 75 weeks. During this time, they will have regular visits to check their blood sugar, weight, blood pressure, and overall health. The study will also ask participants questions about their quality of life and satisfaction with their diabetes treatment. Safety will be carefully monitored throughout the study, including checking for side effects and episodes of low blood sugar, which can occur when blood sugar drops too low and may cause symptoms like shakiness or confusion.

The purpose of the study is to see if empasiprubart can help improve the ability to perform daily activities compared to placebo. The study will also look at how safe the medication is and how well it is tolerated by people with this nerve condition. Researchers want to understand if this treatment can help reduce disability and improve quality of life for people living with this condition.

The study is divided into two parts and will last up to about two years for each person who takes part. During the study, empasiprubart will be given through a needle into a vein, which is called an infusion. People taking part will have regular visits where doctors will check their muscle strength, ability to perform daily tasks, grip strength, and overall well-being. The study will also measure various safety aspects including blood tests, heart function tests, and any side effects that may occur. Throughout the study, researchers will collect blood samples to measure the levels of the medication in the body and to see how the immune system responds to the treatment.

The purpose of this study is to evaluate how safe the treatment is, how well it is tolerated by children, and whether it shows early signs of working to help with the condition. The study will look at whether the treatment causes any side effects or health problems and will also examine whether there are any early benefits for children with this syndrome. During the study, doctors will carefully monitor the children through various tests including blood tests, urine tests, tests of the fluid around the brain and spinal cord, heart monitoring with electrocardiogram and echocardiogram, brain wave recordings with electroencephalographic tests, and brain imaging with MRI scans. The study will also check for the presence of antibodies against the viral vector used to deliver the gene therapy.

The study involves giving a single dose of the gene therapy medicine through injection into both sides of the brain. Children participating in the study will need to live within one hour of the treatment center for at least four months after receiving the medicine, and this time period might be extended if any safety concerns arise. The children will be monitored closely with regular visits and tests to track their safety and any changes in their condition. Before receiving the treatment, children must have stable medication use for at least 28 days, and they cannot participate in any other research studies while enrolled in this one. The study is divided into two parts, with Part A including older children aged 6 to 12 years and Part B including younger children aged 2 to 12 years.

The study involves two groups of participants – one receiving rocatinlimab injections under the skin along with topical treatments, and another receiving placebo injections with the same topical treatments. The treatment period lasts for 24 weeks, during which the effectiveness of the medication will be evaluated by examining improvements in skin appearance and reduction in disease severity.

Throughout the study, doctors will monitor how well the treatment works by checking if participants’ skin becomes clearer and if their symptoms, such as itching and skin pain, improve. They will pay special attention to how the treatment affects different areas of the body, including the face and hands, in people who have atopic dermatitis in these locations.

The purpose of this study is to find out if ziltivekimab works better than placebo in reducing the risk of death from heart and blood vessel problems and preventing heart failure events such as hospital stays or urgent visits for worsening heart failure. The study will also look at other health outcomes including the combined risk of death from heart problems, heart attacks, and strokes, as well as how the treatment affects kidney function, quality of life, and inflammation levels in the body. Quality of life will be measured using questionnaires that ask about symptoms and daily activities.

During the study, participants will receive monthly injections for up to 48 months. The study will track various health events including hospitalizations for heart failure, deaths, heart attacks, strokes, and changes in heart and kidney function. Blood tests will be done to measure inflammation markers like hs-CRP and heart stress markers like NT-proBNP. Heart function will be checked using echocardiography, which is an ultrasound test that creates pictures of the heart. The study will continue until enough information has been collected to determine whether ziltivekimab is effective in helping people with this type of heart failure and inflammation.

The purpose of this research is to determine if mezagitamab can reduce the amount of protein in the urine of people with Primary IgA Nephropathy. During the study, participants will receive either mezagitamab or placebo injections for up to 104 weeks (2 years). The medication or placebo will be given alongside their usual kidney disease treatments.

The study will monitor changes in kidney function and the amount of protein in participants’ urine throughout the treatment period. Researchers will also check for signs of improvement in other symptoms related to kidney disease, including the presence of blood in the urine. The study will track how well participants’ bodies respond to the treatment and measure the amount of medication in their blood.

The medication used in this procedure is bleomycin sulfate, which is administered as a solution for injection. During the study, participants undergo the treatment, and their progress is monitored over time. This includes using MRI, a type of imaging that uses magnetic fields to create detailed pictures of the body, to check for changes in the size of the affected area. The follow-up periods occur at three months and twelve months after the procedure to evaluate how well the treatment worked and to monitor any side effects.

Participants in this trial will receive either the study drug, remibrutinib, in the form of a film-coated tablet taken by mouth, or a placebo. The purpose of the study is to determine if this treatment can help delay the progression of disability. During the study, individuals will be monitored over a period of time to observe how the medication affects their physical abilities and overall health.

The purpose of the study is to assess how Dazodalibep affects the systemic manifestations, or widespread symptoms, of Sjögren’s Syndrome in participants who have moderate-to-severe disease activity. Participants in the study will receive either Dazodalibep or a placebo over a period of time, and their health will be monitored to observe any changes in their condition. The study will last for several weeks, and participants will undergo regular assessments to track their progress and any side effects they may experience.

Throughout the study, researchers will collect data on various health indicators, such as changes in disease activity scores and other symptoms related to Sjögren’s Syndrome. This information will help determine the potential benefits and risks of using Dazodalibep as a treatment option for this condition. The study is designed to provide valuable insights into the management of Sjögren’s Syndrome and to explore new possibilities for improving the quality of life for those affected by this disease.

The purpose of the study is to assess how well Dazodalibep works in reducing the symptoms of Sjögren’s Syndrome in people who experience moderate to severe symptoms. Participants in the study will receive either the treatment or a placebo, which is a substance with no active medication. The study will last for several weeks, during which participants will have regular check-ups to monitor their symptoms and overall health.

Throughout the study, participants will be asked to report on their symptoms and any changes they experience. The goal is to determine if Dazodalibep can provide relief from the symptoms of Sjögren’s Syndrome and to ensure that it is safe for use. The study will help researchers understand the potential benefits and any side effects of the treatment.

The purpose of this study is to show whether empasiprubart works better than human normal immunoglobulin in improving the ability to perform daily activities in adults with this nerve condition. During the study, participants will be randomly assigned to receive either empasiprubart or human normal immunoglobulin through a vein. The study uses a double-dummy design, which means that all participants will receive two infusions to ensure that neither the participants nor the doctors know which treatment is being given. The main assessment will happen at week 24, when doctors will measure changes in functional ability using a scoring system that evaluates arm and leg function.

Throughout the study, various measurements will be taken to assess how well participants can perform daily tasks, their muscle strength, their walking ability, and their overall quality of life. Grip strength will be measured regularly, and participants will complete questionnaires about their disability, fatigue, pain, and general health status. Blood samples will be taken to measure drug levels and to check for any immune responses to the treatment. Safety will be monitored by tracking any unwanted effects, changes in laboratory tests, heart rhythm recordings, and vital signs. The study will also look at how the treatments affect specific proteins in the blood that are involved in the immune response and nerve damage.